



press release

Serentis Appoints Gunnar Staaf as New Commercial Director

Cambridge, UK, [31 March, 2008] – Serentis Limited (“Serentis”), a privately owned biopharmaceutical company, announces today the appointment of Gunnar Staaf as Commercial Director.

Gunnar most recently held the position of European Brand Director for Astellas and was responsible for the Dermatology portfolio including treatments for atopic dermatitis and acne. He has over 13 years of experience in sales and marketing across a number of disease areas including diabetes, psychiatry, osteoporosis and respiratory having worked for Eli Lilly, Novartis as well as Astellas. He holds a BA in Economics and Accounting from Reading University and an MBA from Warwick Business School. At Serentis, Gunnar will be responsible for business development and the commercial growth of the product pipeline.

Tim Sharpington, Chief Executive Officer of Serentis said “We are delighted to welcome Gunnar to the team. Gunnar’s experience in a broad range of commercial roles has given him an in-depth understanding of patient needs and the global pharmaceutical environment. I am confident he will make a real difference in helping to make Serentis a success.”

Notes to Editors:

About Serentis Ltd

Serentis is a privately owned biopharmaceutical company founded in 2006 which objective is to develop a clinical stage pipeline of innovative proprietary products which address unmet medical needs in the field of dermatology.

Products are identified by the in-house, low-risk discovery function and through in-licensing and acquisition of near-clinical stage assets. The Serentis strategy is to establish a clinical stage development pipeline and to move rapidly to clinical proof-of-principle testing with its lead compounds.

Serentis Ltd 23 Cambridge Science Park Milton Road Cambridge CB4 0EY UK
telephone +44 (0) 1223 432500 fax: +44 (0) 1223 432501 email info@serentis-pharma.com www.serentis-pharma.com

Internal research is focused on repositioning existing drugs and their templates in dermatological conditions. Serentis optimises its products for targets indications via both chemical modification and reformulations. This approach allows Serentis to establish clinical proof-of-principle early in the development of a project, and avoids the risk and cost associated with the initial development of new chemical entities. Projects target dermatological conditions characterised by clear unmet need and validated biological targets.

Serentis' in-licensing strategy is to license or acquire assets which are in, or close to, clinical development. The company is actively looking for products and technologies at this stage of development with application in the area of dermatology.

The management team includes seasoned professionals with a track record of delivering fast, efficient development programmes with clear commercial positioning.

Serentis operates an outsourcing business model and has an established network of research and development partners.

For further information about Serentis please visit www.serentis-pharma.com

Enquiries:

- Tim Sharpington, Serentis, CEO on +44 (0) 1223 432500 or timsharpington@serentis-pharma.com
- Peter Keen, Serentis, Corporate Development and Finance Director on +44 (0) 1223 432500 or peterkeen@serentis-pharma.com